Association of IREB2 and CHRNA3 Polymorphisms with Airflow Obstruction in Severe Alpha-1 Antitrypsin Deficiency

Citation
Kim, Woo Jin, Alice M. Wood, Alan F. Barker, Mark L. Brantly, Edward J. Campbell, Edward Eden, Gerard McElvaney, et al. 2012. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respiratory Research 13(1): 16.

Published Version
doi:10.1186/1465-9921-13-16

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:873553

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency

Woo Jin Kim1, Alice M Wood2, Alan F Barker3, Mark L Brantly4, Edward J Campbell5, Edward Eden6, Gerard McElvaney7, Stephen I Rennard8, James M Stocks9, James K Stoller11, Charlie Strange12, Gerard Turino13, Edwin K Silverman14, Robert A Stockley15 and Dawn L DeMeo14*

Abstract

Background: The development of COPD in subjects with alpha-1 antitrypsin (AAT) deficiency is likely to be influenced by modifier genes. Genome-wide association studies and integrative genomics approaches in COPD have demonstrated significant associations with SNPs in the chromosome 15q region that includes CHRNA3 (cholinergic nicotine receptor alpha3) and IREB2 (iron regulatory binding protein 2). We investigated whether SNPs in the chromosome 15q region would be modifiers for lung function and COPD in AAT deficiency.

Methods: The current analysis included 378 PIZZ subjects in the AAT Genetic Modifiers Study and a replication cohort of 458 subjects from the UK AAT Deficiency National Registry. Nine SNPs in LOC123688, CHRNA3 and IREB2 were selected for genotyping. FEV1 percent of predicted and FEV1/FVC ratio were analyzed as quantitative phenotypes. Family-based association analysis was performed in the AAT Genetic Modifiers Study. In the replication set, general linear models were used for quantitative phenotypes and logistic regression models were used for the presence/absence of emphysema or COPD.

Results: Three SNPs (rs2568494 in IREB2, rs8034191 in LOC123688, and rs1051730 in CHRNA3) were associated with pre-bronchodilator FEV1 percent of predicted in the AAT Genetic Modifiers Study. Two SNPs (rs2568494 and rs1051730) were associated with the post-bronchodilator FEV1 percent of predicted and pre-bronchodilator FEV1/FVC ratio; SNP-by-gender interactions were observed. In the UK National Registry dataset, rs2568494 was significantly associated with emphysema in the male subgroup; significant SNP-by-smoking interactions were observed.

Conclusions: IREB2 and CHRNA3 are potential genetic modifiers of COPD phenotypes in individuals with severe AAT deficiency and may be sex-specific in their impact.

Keywords: CHRNA3, Chronic obstructive pulmonary disease, Genetic association analysis, Genetic modifiers, IREB2

Background

Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by persistent airflow limitation. COPD risk likely results from the cumulative effect of environmental factors (especially cigarette smoking), genetic factors, and gene-by-environment interactions [1]. Alpha-1 antitrypsin (AAT) deficiency, typically caused by homozygosity for the Z allele at the AAT gene (SERPINA1), is a proven genetic cause of COPD. However, the development of COPD and emphysema in subjects with AAT deficiency is highly variable and is likely influenced by modifier genes and environmental factors [2-4].

Spirometric measurements of pulmonary function are widely used phenotypes in evaluating AAT deficient subjects and monitoring lung function decline [5]; CT scan assessments for emphysema have been used as...
additional intermediate phenotypes of COPD to overcome some of the heterogeneity inherent in spirometric classifications alone. Familial aggregation studies of pulmonary function have suggested additional modifier genes in AAT deficiency subjects [6,7]. A few potential AAT candidate modifier genes, including NOS3 [8], GSTP1 [9], TNF [10], and IL10 [11], have been reported so far, but these results have not been consistently replicated.

Genome-wide association (GWA) studies have revolutionized the identification of susceptibility genes for complex diseases. Three recent GWA studies showed that SNPs in a region of chromosome 15q25 were significantly associated with lung cancer; several nicotinic acetylcholine receptor genes, including CHRNA3 and LOC123688, are located in this region [12-14]. A genome-wide association (GWA) study in COPD also showed significant associations between COPD susceptibility and SNPs in this region [15]. This region was also associated with airflow obstruction and emphysema [16,17]. Interestingly, in addition to nicotinic acetylcholine receptor genes, this region also includes IREB2 (iron regulatory binding protein 2). IREB2 was identified as a potential COPD susceptibility gene using an integrative genomics approach with gene expression analysis of lung tissue samples followed by genetic association analysis [18]. We hypothesized that SNPs in this chromosome 15q region may be modifiers of intermediate phenotypes of COPD in subjects with severe AAT deficiency.

Methods

Study subjects

The current analysis included 378 subjects with severe AAT deficiency (protease inhibitor [PI] ZZ) from 167 families in the AAT Genetic Modifiers Study. Ascertainment of eligible sibling pairs was based on homozygosity for the Z allele at the SERPINA1 locus as previously described [19]. Pre- and post-bronchodilator study spirometry testing was performed according to American Thoracic Society (ATS) standards as described previously [19]. Percent predicted values for FEV1 were calculated using equations of Crapo and colleagues for Caucasian subjects [20]. The FEV1/FVC ratio was analyzed using unadjusted values. Pack-years of cigarette smoking were calculated by multiplying the number of years smoked by the average number of daily cigarettes smoked, divided by 20. All participants provided written informed consent, and the study protocol was approved by individual Institutional Review Boards at each of the participating clinical centers (Partners IRB, 2001P001237). 458 unrelated Caucasian subjects from the UK AATD National Registry were also genotyped. Approval for the study was given by the local ethics committee. All patients had a serum alpha-1 antitrypsin (AAT) level of < 11 μM and PI ZZ genotype confirmed by allele-specific PCR (Hereditab, Salt Lake City, Utah, USA). None of the UK subjects had ever received AAT augmentation therapy. A full clinical assessment including smoke exposure, presence of chronic bronchitis (defined as a productive cough for at least 3 months in at least 2 consecutive years [21]), lung function testing and high resolution CT scanning of the chest was undertaken, as described previously [22]. The presence of emphysema was determined by the appearance of the scan and density mask analysis of slices at the level of the aortic arch (representing the upper zone) and the inferior pulmonary vein (representing the lower zone) using a threshold of -910 Hounsfield Units (HU). This HU threshold has been validated against physiological measures in AATD [22]. Patients whose voxel index exceeded values seen in normal subjects in either zone [23] were classified as having emphysema.

Genotyping

Two SNPs (rs8034191 and rs1051730) in chromosome 15 were selected from the previous GWA in COPD [15]. Additionally, 7 SNPs in IREB2 were selected using pairwise linkage disequilibrium (LD)-tagging in Tagger with a minimum minor allele frequency of 0.05 and r2-threshold of 0.8 [24]. SNPs were genotyped using Sequenom (San Diego, CA) assays in the AAT Genetic Modifiers Study. All family data were evaluated for familial inconsistencies using the PEDCHECK program [25].

In UK AATD National Registry study, genotyping was carried out using TaqMan® technologies (Applied Biosystems, UK) on an ABI7900 HT for 3 SNPs associated in the test dataset (rs2568494, IREB2; rs8034191, LOC123688; rs1051730, CHRNA3). All genotyping assays were pre-validated by the suppliers, and all plates included appropriate negative controls.

Statistical analysis

Hardy-Weinberg equilibrium was assessed using goodness of fit tests. Pre- and post-bronchodilator FEV1 percent of predicted and pre- and post-bronchodilator FEV1/FVC ratio were analyzed as quantitative phenotypes. Family-based association analysis was performed using PBAT software version 3.6 [26] assuming additive genetic models, adjusting for pack-years and pack-years of cigarette smoking, under the null hypothesis of no linkage and no association in the AAT Genetic Modifiers Study. In addition to the overall model, we evaluated gender-stratified models and models that included a SNP-by-smoking or a SNP-by-gender interaction term. Haplotype analysis was performed using 8, 4, 3, 2 SNP adjacent sliding windows in PBAT.

In the UK AATD National Registry study, data were analyzed using SPSS (version 16, Chicago: SPSS Inc). Quantitative genetic association analysis was carried out
for FEV₁ and FEV₁/FVC using general linear models, adjusting for age, gender and smoke exposure (as pack-years and pack-years²). Logistic regression models were used for the presence of emphysema or COPD (defined as post bronchodilator FEV₁/FVC < 0.7) accounting for covariates as before. Additive models were assumed for all SNPs. Gender stratification and SNP-by-gender and SNP-by-smoking interaction analyses were also carried out, as in the test dataset.

Results

Demographic characteristics
The mean age of subjects was 52.2 years, and mean post-bronchodilator FEV₁ was 65.9% predicted in the AAT Genetic Modifiers Study and 50.3 years and 53.8% predicted in the UK AATD National Registry, respectively (Table 1). Male subjects were 46% in AAT Genetic Modifiers Study and 59% in UK AATD National Registry, respectively. Three hundred and sixty-six subjects (79.8%) had emphysema in UK AATD National Registry.

Association analysis
There were no deviations from Hardy Weinberg equilibrium for any of the genotyped SNPs.

In the AAT Genetic Modifiers Study, three SNPs (rs2568494 in IREB2, rs8034191 in LOC123688, and rs1051730 in CHRNA3) were associated with pre-bronchodilator FEV₁ percent of predicted (p < 0.05 Table 2 Figure 1). Two SNPs (rs2568494 and rs1051730) were associated with post-bronchodilator FEV₁ percent of predicted and pre-bronchodilator FEV₁/FVC ratio. One SNP (rs1051730) was associated with post-bronchodilator FEV₁ percent of predicted and pre-bronchodilator FEV₁/FVC ratio. One SNP (rs1051730) was associated with post-bronchodilator FEV₁/FVC ratio (Table 2). Linkage disequilibrium (assessed with r²) between rs8034191 and the 1051730 was 0.9 (Figure 2). There was significant association only with a 2 SNP haplotype including rs8034191 and rs1051730 with pre-bronchodilator FEV₁/FVC ratio (global test statistic; p = 0.05) using PBAT.

Interactions with cigarette smoking
There was no association between any of the genotyped SNPs and pack-years of smoking as the outcome in the AAT Genetic Modifiers Study. Inclusion of a SNP-by-pack-years interaction term for the lung function phenotypes showed significant interaction of rs1051730 with pack-years of smoking for the pre-bronchodilator FEV₁/FVC ratio (main effect; p = 0.02, interaction effect; p = 0.04). There was no significant association with lung function phenotypes when the study population was stratified into groups of ever-smokers (n = 233) and never-smokers (n = 145) although this stratified analysis reduced the number of informative families considerably.

Genotype-by-gender interactions and gender stratification
SNP-by-gender interaction analysis showed significant interaction of rs2568494, rs8034191, and rs1051730 with gender in models for the post-bronchodilator FEV₁/FVC ratio (main effect; p = 0.04, 0.04, 0.02, interaction effect; p = 0.02, 0.008, 0.004, respectively). Additionally, rs1051730 showed significant interaction in models for pre and post-bronchodilator FEV₁ and pre-bronchodilator FEV₁/FVC ratio (main effect; p = 0.04, 0.04, 0.08, interaction effect; p = 0.04, 0.02, 0.04, respectively).

In the stratified analysis, for the male subgroup, the p values were similar to the whole cohort results, with rs8034191 showing significant association with pre- and post-bronchodilator FEV₁ percent of predicted and post-bronchodilator FEV₁/FVC ratio (Table 3). However, in the female subgroup, there was no significant association with lung function phenotypes.

Replication analysis
In the initial analyses in the whole UK dataset, no significant associations with quantitative phenotypes including FEV₁ and FEV₁/FVC and qualitative presence of emphysema and COPD were observed (all p > 0.05). Gender interaction was apparent for rs2568494 with both COPD and emphysema (main effect p = 0.10, interaction p = 0.04 and 0.06, 0.03 respectively). No other statistically significant gender interactions were observed. In the sex-stratified models, evidence of association for SNPs in IREB2 and LOC123688 was observed. A trend

Table 1 Baseline characteristics for PI ZZ individuals in the AAT Genetic Modifiers Study and the UK AATD National Registry

| Characteristics | AAT Genetic Modifiers Study (n = 378) | UK national registry for AATD (n = 458) | p value |
|-----------------|---------------------------------------|----------------------------------------|---------|
| Age, years      | 52.2 ± 9.7                            | 50.3 ± 10.4                            | 0.01    |
| Male sex (%)    | 173 (46%)                             | 252 (55%)                              | < 0.0001|
| FEV₁% predicted | 65.9 ± 33.5                           | 53.8 ± 32.2                            | 0.0001  |
| FEV₁/FVC        | 0.51 ± 0.207                          | 0.445 ± 0.194                          | < 0.0001|
| Pack-years for ever smokers | 18.2 ± 14.5                          | 15.9 ± 14.7                            | < 0.0001|

Data are presented as means (± S.D.) in the AAT Genetic Modifiers Study and the UK national registry for AATD, unless otherwise noted.
was observed for association of rs8034191 and rs2568494 with COPD in the male subgroup, the risk alleles being C and A respectively (both \( p = 0.09 \)). The SNP rs2568494 in IREB2 was significantly associated with emphysema in the male subgroup, the A allele conferring an odds ratio and 95% confidence interval (OR and 95% CI) of disease of 2.67 (1.10-6.51, \( p = 0.03 \)). No association was seen with rs1051730 with emphysema. With addition of a SNP-by-smoking interaction term, both rs8034191 and rs2568494 were associated with COPD in the male subgroup (main effect, \( p = 0.03 \); interaction effect, \( p = 0.02 \); and main effect, \( p = 0.04 \); interaction effect, \( p = 0.003 \), respectively). Similar associations with emphysema were seen for rs2568494 (\( p = 0.03 \) and 0.02 respectively). Positive findings in the two datasets are summarized in Table 4.

Table 2 Genetic association results between SNPs in chromosome 15 and lung function in the AAT Genetic Modifiers Study

| Gene     | SNP     | MAF  | pre-FEV\(_1\)% predicted | post-FEV\(_1\)% predicted | pre-FEV\(_1\)/FVC | post-FEV\(_1\)/FVC |
|----------|---------|------|---------------------------|---------------------------|------------------|------------------|
| IREB2    | rs2568494 intron | 0.30 | 0.02*                     | 0.03*                     | 0.05*            | 0.06             |
|          | rs2656069 intron  | 0.22 | 0.48                      | 0.29                      | 0.59             | 0.46             |
|          | rs1964678 intron  | 0.43 | 0.75                      | 0.91                      | 0.58             | 0.83             |
|          | rs12593229 intron | 0.43 | 0.82                      | 0.79                      | 0.64             | 0.93             |
|          | rs10851906 intron | 0.23 | 0.29                      | 0.17                      | 0.41             | 0.31             |
|          | rs965604 intron   | 0.43 | 0.76                      | 0.99                      | 0.54             | 0.65             |
|          | rs13180 exon      | 0.43 | 0.69                      | 0.96                      | 0.53             | 0.79             |
| LOC123688| rs8034191 intron  | 0.29 | 0.04*                     | 0.07                      | 0.09             | 0.14             |
| CHRNA3   | rs1051730 exon    | 0.31 | 0.02*                     | 0.03*                     | 0.03*            | 0.05*            |

MAF = minor allele frequency
Each model was analyzed assuming an additive mode of inheritance adjusting for pack-years and pack-years\(^2\)
* \( p \leq 0.05 \)

was observed for association of rs8034191 and rs2568494 with COPD in the male subgroup, the risk alleles being C and A respectively (both \( p = 0.09 \)). The SNP rs2568494 in IREB2 was significantly associated with emphysema in the male subgroup, the A allele conferring an odds ratio and 95% confidence interval (OR and 95% CI) of disease of 2.67 (1.10-6.51, \( p = 0.03 \)). No association was seen with rs1051730 with emphysema. With addition of a SNP-by-smoking interaction term, both rs8034191 and rs2568494 were associated with COPD in the male subgroup (main effect, \( p = 0.03 \); interaction effect, \( p = 0.02 \); and main effect, \( p = 0.04 \); interaction effect, \( p = 0.003 \), respectively). Similar associations with emphysema were seen for rs2568494 (\( p = 0.03 \) and 0.02 respectively). Positive findings in the two datasets are summarized in Table 4.

| Gene     | SNP     | MAF  | pre-FEV\(_1\)% predicted | post-FEV\(_1\)% predicted | pre-FEV\(_1\)/FVC | post-FEV\(_1\)/FVC |
|----------|---------|------|---------------------------|---------------------------|------------------|------------------|
| IREB2    | rs2568494 intron | 0.30 | 0.02*                     | 0.03*                     | 0.05*            | 0.06             |
|          | rs2656069 intron  | 0.22 | 0.48                      | 0.29                      | 0.59             | 0.46             |
|          | rs1964678 intron  | 0.43 | 0.75                      | 0.91                      | 0.58             | 0.83             |
|          | rs12593229 intron | 0.43 | 0.82                      | 0.79                      | 0.64             | 0.93             |
|          | rs10851906 intron | 0.23 | 0.29                      | 0.17                      | 0.41             | 0.31             |
|          | rs965604 intron   | 0.43 | 0.76                      | 0.99                      | 0.54             | 0.65             |
|          | rs13180 exon      | 0.43 | 0.69                      | 0.96                      | 0.53             | 0.79             |
| LOC123688| rs8034191 intron  | 0.29 | 0.04*                     | 0.07                      | 0.09             | 0.14             |
| CHRNA3   | rs1051730 exon    | 0.31 | 0.02*                     | 0.03*                     | 0.03*            | 0.05*            |

MAF = minor allele frequency
Each model was analyzed assuming an additive mode of inheritance adjusting for pack-years and pack-years\(^2\)
* \( p \leq 0.05 \)

Discussion
SNPs in the chromosome 15 CHRNA3/CHRNAS/LOC123688/IREB2 region have been shown to have associations with lung cancer and COPD unrelated to AAT deficiency. In our current analysis, SNPs in IREB2, LOC123688 and CHRNA3 genes were shown to be associated with lung function phenotypes in AAT deficient subjects (all PI ZZ) from the AAT Genetic Modifiers Study, and suggested a potential sex-specific effect. Replication in another cohort of AAT deficient subjects from the UK showed that a SNP in IREB2 was also associated with emphysema in men. This suggests that chromosome 15q region genes that were found by GWA studies and gene expression analysis of lung tissue samples may also be modifier genes of COPD and emphysema in AAT deficient subjects.
CHRNA3 was associated with lung cancer in three separate large GWA studies. This gene was associated with COPD by GWA and the association was replicated in two other COPD cohorts. There have also been recent reports of an association with smoking addiction [27], so it is unclear whether the lung cancer and COPD associations relate to smoking behavior, another aspect of lung biology, or both. CHRNA3 is a subunit gene of the nicotinic cholinergic receptor and expressed in autonomic ganglia and brain but is also expressed in bronchial and non-bronchial epithelial cells [28]. Expression in lung cancer cells and signal transduction and apoptosis studies suggests a potential role in carcinogenesis [29]. Interestingly, there are not many observations of lung cancer in patients with AAT deficiency, perhaps because of mortality associated with the development of severe COPD at an early age. Whether there is a common mechanism unrelated to smoking in the pathogenesis of lung cancer and COPD, or whether these previously reported associations relate to smoking addiction is unclear.

IREB2 is a protein of iron-responsive elements (IREs) and is regulated in response to iron and oxygen supply [30]. IREB2−/− mice have aberrant iron homeostasis and accumulate iron in the intestine and the central nervous system (CNS); the CNS accumulation may lead to neurodegenerative disease [31]. Excess iron can be toxic, but the mechanism of neurodegenerative disease is unclear; work is in progress to further characterize the functional pathways impacted by IREB2 in the lung. IREB2 was found to be differentially expressed according to lung function by microarray experiments, and the SNPs in IREB2 showed associations in both a COPD case-control study and family-based studies including the Boston Early-onset COPD and International COPD Genetics Network studies [18]. In a recent report, IREB2 polymorphisms were associated with COPD susceptibility in a European population [32]. Interestingly, rs2568494 was significantly associated with COPD in three studies including our current study.

Previous studies of AAT deficient subjects showed that lung function was lower in men than women [33], and previous analyses in the AAT Genetic Modifiers Study also showed lower lung function in men [19]. Our current study suggests that genetic modifier effects of IREB2 and CHRNA3 may be more prominent in males—potentially contributing to some of the sex-specific features of COPD susceptibility and severity among PI ZZ subjects, although a larger sample size is needed to verify a gene-by-sex interaction.

In this study, there was no association between IREB2 and CHRNA3 genes and smoking intensity. In the AAT Genetic Modifiers Study, results showed no association when the cohort was stratified by smoking history (ever smokers versus never smokers). However, there was a marginal interaction of rs1051730 with smoking. In the

### Table 3 Genetic association results between SNPs in chromosome 15 and lung function of male subgroup in the AAT Genetic Modifiers Study cohort

| Gene   | SNP    | P-values for Different Phenotypes | P-values for Different Phenotypes |
|--------|--------|----------------------------------|----------------------------------|
|        |        | pre-FEV1% predicted | post-FEV1% predicted | pre-FEV1/FVC | post-FEV1/FVC |
| IREB2  | rs2568494 intron | 0.03* | 0.04* | 0.07 | 0.03* |
|        | rs2650069 intron | 0.97 | 0.87 | 0.64 | 0.65 |
|        | rs196478 intron  | 0.99 | 0.96 | 0.85 | 0.78 |
|        | rs12593229 intron | 0.95 | 0.93 | 0.87 | 0.76 |
|        | rs10851906 intron | 0.70 | 0.61 | 0.84 | 0.80 |
|        | rs965604 intron  | 0.84 | 0.90 | 0.75 | 0.70 |
|        | rs13180 exon     | 0.85 | 0.91 | 0.76 | 0.71 |
| LOC123688 | rs8034191 intron | 0.04* | 0.04* | 0.12 | 0.04* |
| CHRNA3 | rs1051730 exon   | 0.02* | 0.02* | 0.07 | 0.02* |

Each model was analyzed assuming an additive mode of inheritance adjusting for pack-years and pack-years²

*p ≤ 0.05

| Table 4 Positive findings of genetic association analysis in the AAT Genetic Modifiers Study and the UK AATD National Registry |
|--------------------------------------------------------------------------------------------------------------------------|
| AAT Genetic Modifiers Study | UK AATD National Registry |
|----------------------------|---------------------------|
| All subjects                | Association with pre- and post- FEV1% predicted and pre- and post- FEV1/FVC | none |
| Interaction with gender     | yes | yes |
| Interaction with smoking    | yes | only in the male subgroup |
| Male subgroup               | association with FEV1 and FEV1/FVC | association with emphysema association with COPD after adding smoking interaction term |

Kim et al. Respiratory Research 2012, 13:16
http://respiratory-research.com/content/13/1/16

Page 5 of 7
UK study, there were significant smoking interactions of rs2568494 and rs8034191. Smoking markedly increases the risk of COPD and lowers the age-of-onset of COPD in AAT deficient subjects [6,19], and despite small sample sizes, we found reasonable evidence for gene-by-smoking interactions in the chromosome 15q region.

There are several limitations in this study. Multiple statistical comparisons are a potential concern in any complex disease genetics study. Adjusting for either 3 genes or 9 SNPs tested, a p value of 0.02 is marginal. Additionally, the association with pulmonary function did not replicate in the UK population, potentially due to phenotypic heterogeneity between the two cohorts. Specifically, the UK subjects have lower mean FEV1 and potentially more emphysema, both of which could influence non-replication. Of note, the association with emphysema was investigated only in the UK population as chest CT scan data collection was not part of the AAT Genetic Modifiers Study. Considering that these SNPs (rs2568494 in IREB2, rs8034191 in LOC123688, and rs1051730 in CHRNA3) were associated with intermediate phenotypes of COPD in other populations and that we include an independent AAT deficient replication cohort, our result are likely meaningful. Additionally, this test-replication approach is even more appealing since all subjects were homozygous recessive for the AAT risk locus (PI ZZ). Also, replication of our results showed association with emphysema, a less heterogeneous pulmonary phenotype. The associated SNPs included two intronic (rs2568494, rs8034191) and one synonymous exonic (rs1051730) SNP. The exonic SNP was not associated with COPD-related phenotypes in the UK cohort. Another limitation of our current study is that rare functional variants in this chromosome 15 region may be contributing to the role of these genes in COPD; genome sequencing efforts in AAT deficient cohorts would be valuable to study rare variant associations. Functional data for associated variants are currently lacking, but many groups are pursuing functional work on this chromosome 15 region.

Conclusion
We have identified that the chromosome 15q25 region likely contains at least one potential modifier gene of COPD phenotypes in individuals with severe AAT deficiency. The association may be due to smoking behavior, but this is less likely; additionally, these associations may have sex-specific effects. Future directions will include further evaluation of the gene-by-sex interaction in larger cohort with AAT deficiency and identification of the functional variant or variants in this region.

Abbreviations
AAT: Alpha-1 antitrypsin; CHRNA3: Cholinergic nicotine receptor alpha3; GWA: Genome-wide association; IREB2: Iron regulatory binding protein 2; MAF: Minor allele frequency

Acknowledgements
This work was supported by US National Institutes of Health [Grant R01 HL68026, R01 HL75478, R01 HL04323, P01 HL083069 (EKS) and HL089438]. The UK AATD Registry was supported by an unrestricted grant by Talecris as part of the ADAPT program. Additionally, DLD is supported by a Clinician Scientist Development Award from the Doris Duke Foundation.

Author details
1 Department of Internal Medicine, Kangwon National University, Chuncheon, South Korea 2 School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK 3 Oregon Health and Science University, Portland, OR, USA 4 University of Florida, Gainesville, FL, USA 5 Intermountain Health Care, Provo, and Heredilab, Inc, Salt Lake City, UT, USA 6 St. Luke’s Roosevelt Hospital, New York, NY, USA 7 Beaumont Hospital, Dublin, Ireland 8 University of Nebraska, Omaha, NE, USA 9 National Jewish Health, Denver, CO, USA 10 University of Texas at Tyler, Tyler, TX, USA 11 Cleveland Clinic, Cleveland, OH, USA 12 Medical University of South Carolina, Charleston, SC, USA 13 St. Luke’s/ Roosevelt Hospital, New York, NY, USA 14 Channing Laboratory and the Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA 15 Lung Investigation Unit, University Hospitals Birmingham, Birmingham, UK.

Authors’ contributions
All authors contributed to the study design, data collection and analysis, and writing of the manuscript. WJK, AMW, DLD contributed to data analysis. All authors read and approved the final manuscript.

Competing interests
WJK, AMW, AFB, MLD, EJC, EE, GM, RAS and GT have reported that no potential conflicts of interest. SIR was supported from GlaxoSmithKline for travel to meetings for the study. JMS received grant support from Talecris, Baxter. JKS received grant support from AstraZeneca, and honoraria from Talecris, Baxter, CSL Behring, Boehringer Ingelheim, Kamada, Grifols, and has received fees for participation in review activities from Shire and AsthmaTx. CS received consulting fees from AstraZeneca, Talecris, Baxter, Forest, Pharmaceuiticals, Uptake Medical, Pulmonx and payment for lectures from Talecris and AstraZeneca. EKS received grant support and consulting fees from GlaxoSmithKline for studies of COPD genetics and honoraria and consulting fees from AstraZeneca. RAS received grant support, honoraria and consulting fees and supported for travel to meetings for the study from Talecris. DLD received grant support from Doris Duke Charitable Foundation.

Received: 11 December 2011 Accepted: 22 February 2012
Published: 22 February 2012

References
1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Gold executive summary. Am J Respir Crit Care Med 2007, 176:S32-S55.
2. DeMeo DL, Silverman EK. Alpha-1-antitrypsin deficiency. 2. Genetic aspects of alpha-1-antitrypsin deficiency: Phenotypes and genetic modifiers of emphysema risk. Thorax 2004, 59:259-264.
3. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotype differences in alpha-1-deficient sibling pairs may relate to genetic variation. COPD 2008, 5:333-339.
4. Wood AM, Harrison RM, Semple S, Ayres JG, Stockley RA: Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. Occup Environ Med 2010, 67:556-561.
5. American Thoracic Society/European Respiratory Society statement. Standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003, 168:818-900.
6. Silverman EK, Province MA, Rao DC, Pierce JA, Campbell EJ. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes. Am Rev Respir Dis 1990, 142:1015-1021.
7. DeMeo DL, Campbell EJ, Brantly ML, Barker AF, Eden E, McElvaney NG, Rennard SJ, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK. Heritability of lung function in severe alpha 1-antitrypsin deficiency. Hum Hered 2009, 67:38-45.
8. Novoradovsky A, Brantly ML, Waclawiak MA, Chaudhry PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehmcrantr ME, Rogglians P, Moss J. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha 1-antitrypsin deficiency. Am J Respir Cell Mol Biol 1999, 20:241-447.
9. Rodriguez F, de la Roza C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione s-transferase p1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest 2005, 127:1537-1543.
10. Wood AW, Simmonds MJ, Bayley DL, Nevbvy PR, Gough SC, Stroclly RA. The TNfalpha gene relates to clinical phenotype in alpha 1-antitrypsin deficiency. Respir Res 2008, 9:52.
11. DeMeo DL, Campbell EJ, Brantly ML, Eden E, McEvaneay NG, Rennard SJ, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK. IL-10 polymorphisms are associated with airflow obstruction in severe alpha 1-antitrypsin deficiency. Am J Respir Cell Mol Biol 2005, 43:1537-1543.
12. Thorgerisson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Magnusson KP, Magnusson KP. Heritability of pulmonary function in severe alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 2010, 181:1498-1505.
13. Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK. Identifiers which are freely available for redistribution
14. The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. PLoS Genet 2011, 7:124-31.
15. Piitulainen E, Tornling G, Eriksson S: Iron metabolism and the ire/irp regulatory system: An update. Ann NY Acad Sci 2005, 1049:148-36.
16. DeMeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SJ, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009, 85:493-502.
17. DeMeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SJ, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK. Determinants of airflow obstruction in severe alpha 1-antitrypsin deficiency. Thorax 2007, 62:806-813.
18. Crapo RO, Gardner RW: Reference spirometric values using techniques and equipment that meet current recommendations. Am Rev Respir Dis 1982, 126:659-664.
19. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965, 285:775-779.
20. Dowson LJ, Guest PJ, Hill SS, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: Relationship to lung function and health status. Eur Respir J 2001, 17:1097-1104.
21. Sasaki CN, Hinrichs AL, Saccozzi NL, Chase GA, Kornick K, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau L, Swan GE, Goate AM, Rutter J, Bertelsen S, Fox L, Fugman D, Martin NG, Montgomery GW, Tang JC, Ballinger DG, Rice JP, Bierut LJ. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007, 16:36-49.
22. Arrendondo J, Chernyavsky AJ, Marubio LM, Beaudot AL, Jolivold CY, Pinkerton KE, Grando SA. Receptor-mediated tobacco toxicity: Regulation of gene expression through alpha3betta2 nicotinic receptor in oral epithelial cells. Am J Pathol 2005, 166:597-613.
23. West KA, Broughard J, Clark AS, Linnorna IR, Yang X, Swan SM, Harris C, Belinsky S, Dennis PA. Rapid A4 activation by nicotine and a tobacco caricgen modulate the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111:81-90.
24. Pantopoulos K: Iron metabolism and the ire/irp regulatory system: An update. Ann NY Acad Sci 2004, 1012:1-13.